Founded in 1935 in Mumbai, Cipla is a global pharmaceutical leader focused on developing and delivering affordable, high-quality generic and branded medicines. With over 1,500 products spanning more than 50 dosage forms, Cipla serves over 80 countries and continues its mission of “Caring for Life” through innovation and equitable access to healthcare. It is particularly noted for pioneering affordable HIV/AIDS therapies in developing regions
Company CEO / Managing Director
Mr. Umang Vohra is the Managing Director and Global Chief Executive Officer, leading Cipla's international expansion and R&D initiatives Industry
Pharmaceutical Manufacturing (Generics, APIs, branded formulations, diagnostics, inhaler devices; also active in biosimilars and consumer healthcare)
Ownership Type
Publicly listed company, traded on BSE, NSE (NIFTY 50 constituent), and GDRs listed on the Luxembourg Stock Exchange. The promoter family (Hamied family) holds ~34% shareholding Company Details / Business Segments
Generics and branded generics across therapeutic areas including respiratory, HIV/AIDS, cardiovascular, diabetes, oncology, and CNS
Manufacturing of APIs, inhalation devices, and diagnostics
Consumer healthcare via Cipla Health
R&D of novel molecules and delivery systems; Biosimilars through Cipla BioTec
Operations include over 40 manufacturing facilities and presence in 86 countries
Headquarters / Location
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra 400013, India
Website
www.cipla.com
Number of Employees
Approximately 30,313 employees as of March 31, 2025 (up from 27,764 in 2024)
Established In
Cipla was founded in 1935 by Dr. Khwaja Abdul Hamied, originally known as Chemical, Industrial & Pharmaceutical Laboratories (later abbreviated to Cipla in 1984)